Presentation is loading. Please wait.

Presentation is loading. Please wait.

Change in cortical bone thickness among 64 women with osteopenia randomised to 14-month treatment with no mineral therapy (red bar), calcium gluconate.

Published byCarmella Mosley Modified over 5 years ago

Similar presentations

Presentation on theme: "Change in cortical bone thickness among 64 women with osteopenia randomised to 14-month treatment with no mineral therapy (red bar), calcium gluconate."— Presentation transcript:

1 Change in cortical bone thickness among 64 women with osteopenia randomised to 14-month treatment with no mineral therapy (red bar), calcium gluconate (blue bar), or calcium hydroxyapatite (green bar). Change in cortical bone thickness among 64 women with osteopenia randomised to 14-month treatment with no mineral therapy (red bar), calcium gluconate (blue bar), or calcium hydroxyapatite (green bar). The control group showed bone loss (p<0.01 compared to baseline), while the hydroxyapatite group showed bone gain (p<0.01 compared to baseline). The calcium gluconate showed no significant change.70 James H O'Keefe et al. Open Heart 2016;3:e000325 ©2016 by British Cardiovascular Society

Download ppt "Change in cortical bone thickness among 64 women with osteopenia randomised to 14-month treatment with no mineral therapy (red bar), calcium gluconate."

Similar presentations

Distribution of lifespan for men initiating preventative therapy (with a risk reduction of 30%) at the age of 50, with national average blood pressure.

Distribution of lifespan for men initiating preventative therapy (with a risk reduction of 30%) at the age of 50, with national average blood pressure.
Impact of risk factors and age of initiation of therapy on the distribution of lifespan gain. ‘National average risk’ refers to a cohort beginning at age.

Impact of risk factors and age of initiation of therapy on the distribution of lifespan gain. ‘National average risk’ refers to a cohort beginning at age.
Comparison of N. gonorrhoeae gene expression during infection in men and women in vivo. Comparison of N. gonorrhoeae gene expression during infection in.

Comparison of N. gonorrhoeae gene expression during infection in men and women in vivo. Comparison of N. gonorrhoeae gene expression during infection in.
Sudden Unexpected Death in North Carolina (SUDDEN) Gender and Ethnicity by Age—the majority of the cohort is over age 55 years, especially black men but.

Sudden Unexpected Death in North Carolina (SUDDEN) Gender and Ethnicity by Age—the majority of the cohort is over age 55 years, especially black men but.
MACE rate among CAD severity groups (total 0

MACE rate among CAD severity groups (total 0
Bisphosphonate exposure and Atypical Femoral Fractures

Bisphosphonate exposure and Atypical Femoral Fractures
Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.

Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.
Frequency counts of exercise intensities routinely prescribed in programmes (n=194) grouped by method/scale. Frequency counts of exercise intensities routinely.

Frequency counts of exercise intensities routinely prescribed in programmes (n=194) grouped by method/scale. Frequency counts of exercise intensities routinely.
Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
Patients’ preferences do not always match maximisation of lifespan.

Patients’ preferences do not always match maximisation of lifespan.
Endothelial function at baseline and follow-up (responders in white bars and non-responders in black). Endothelial function at baseline and follow-up (responders.

Endothelial function at baseline and follow-up (responders in white bars and non-responders in black). Endothelial function at baseline and follow-up (responders.
Hospital-level procedural sedation rates among pediatric patients in the earliest year, (2009, red circle) and the most recent year (2014, blue bar). Hospital-level.

Hospital-level procedural sedation rates among pediatric patients in the earliest year, (2009, red circle) and the most recent year (2014, blue bar). Hospital-level.
HOMA calculations where glucose is mmol/L and insulin is mU/L

HOMA calculations where glucose is mmol/L and insulin is mU/L
Bar chart of systolic function in healthy individuals, HCM LVH− patients and HCM LVH+ patients. GLS was significantly worse in the HCM LVH+ patients compared.

Bar chart of systolic function in healthy individuals, HCM LVH− patients and HCM LVH+ patients. GLS was significantly worse in the HCM LVH+ patients compared.
(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.

(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.
Peripheral blood eosinophil levels based on a threshold of (A) 150 cells/μL, patients not randomised to inhaled corticosteroids (ICS)-containing treatment.

Peripheral blood eosinophil levels based on a threshold of (A) 150 cells/μL, patients not randomised to inhaled corticosteroids (ICS)-containing treatment.
(A) Meta-analysis of repeat revascularisation in randomised trials.

(A) Meta-analysis of repeat revascularisation in randomised trials.
Metaregression showing the relationship between mortality and antiplatelet strategy. Metaregression showing the relationship between mortality and antiplatelet.

Metaregression showing the relationship between mortality and antiplatelet strategy. Metaregression showing the relationship between mortality and antiplatelet.
(A and B) Changes in the apnoea hypopnoea index (AHI) and 3% oxygen desaturation index (ODI) from baseline to treatment titration and 3 months of therapy:

(A and B) Changes in the apnoea hypopnoea index (AHI) and 3% oxygen desaturation index (ODI) from baseline to treatment titration and 3 months of therapy:

Similar presentations

Ads by Google